

BAYLOR SAMMONS CANCER CENTER

&

THE DEPARTMENT OF INTERNAL MEDICINE
BAYLOR UNIVERSITY MEDICAL CENTER
Dallas, Texas

Present the Annual

2021 Marvin J. Stone Lectureship

“What Does the FUTURE Blood Smear Show?”

by

Daniel Von Hoff, MD

Distinguished Professor and Executive Vice President, Translational Genomics Research Institute (TGen), Professor of Medicine, Mayo Clinic, Virginia G. Piper Distinguished Chair for Innovative Cancer Research and Chief Scientific Officer, Honor Health Research Institute, Medical Director of Research, McKesson Specialty Health and Chair of the Early Drug Development Committee, US Oncology Research

INTERNAL MEDICINE GRAND ROUNDS

Tuesday, September 14, 2021

8:00am

Webinar

Supported in part by the Edward and Ruth Wilkof Foundation



MARVIN J. STONE, MD, MACP, FRCP

Marvin J. Stone, a native of Columbus, Ohio, took his premedical studies at The Ohio State University. In 1962, he received a master of science degree in pathology and, in 1963, the MD with Honors from the University of Chicago. His internship and first-year residency were at Barnes Hospital in St. Louis on the ward medical service. From 1965 to 1968, he was a clinical associate at the National Institutes of Health in Bethesda, Maryland. In 1968, he came to Dallas as a senior resident in medicine at Parkland Memorial Hospital, and the next year was a fellow in hematology-oncology.

Dr. Stone remained in Dallas on the faculty of The University of Texas Southwestern Medical School rising to the rank of associate professor. He moved to Baylor University Medical Center in 1976 to become the first chief of oncology and director of the new Charles A. Sammons Cancer Center, positions he held until 2008.

Dr. Stone served as program director of the Medical Oncology Fellowship at Baylor from 1984 to 2013 and head of the Junior Medical Student Clerkship from 1988 to 2013. He received Outstanding Teacher Awards from the Housestaff at Baylor and from Alpha Omega Alpha medical students at UT Southwestern. He is the author of over 250 articles and book chapters on various aspects of hematology-oncology, particularly monoclonal gammopathies. In 1999, Baylor Health Care System created the Marvin J. Stone Library at the Baylor Institute for Immunology Research.

Dr. Stone is a Master of the American College of Physicians and received the Distinguished Service Award from the University of Chicago in 2002. He is a past president of the American Osler Society. Dr. Stone was honored with the Lifetime Achievement Award in Waldenström's Macroglobulinemia. The Annual Marvin J. Stone Lectureship was established in 2009 and the Marvin J. Stone Medical Oncology Education Center was founded at the Sammons Cancer Center in 2013.

Dr. Stone is Chief Emeritus of Hematology and Oncology at Baylor University Medical Center, Professor of Internal Medicine at Texas A&M College of Medicine and Clinical Professor of Humanities at the University of Texas at Dallas.



Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR is a Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute and the Margaret Givan Larkin Endowed Chair in Developmental Cancer Therapeutics at Hoag Hospital and Medical Director of Research at McKesson Specialty Health and the Chief Scientific Officer for US Oncology Research specializing in phase I clinical trials. He is also Professor of Medicine at the University of Arizona and at the Mayo Clinic, Scottsdale, AZ, and Senior Consultant of Clinical Investigation at the City of Hope.

Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDA-approved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, pexidartinib, and others. His clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for the treatment of patients with advanced pancreatic cancer. At present, he and his colleagues are concentrating on the development of therapies for patients with advanced pancreatic cancer.

Dr. Von Hoff has published more than 741 papers, 143 book chapters, and over 1186 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care and most recently the AACR Distinguished Public Service Award in recognition of his extraordinary clinical research career and leadership in establishing the AACR/ASCO Methods in Clinical Cancer Research Workshop to educate and train young clinical investigators.

Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world's largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Trial Cancer Research Workshop, which has graduated more than 2100 clinical trial physicians. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

PREVIOUS SPEAKERS:

2009 – Steven P. Treon, MD, PhD

2010 – Robert A. Kyle, MD

2011 – James O. Armitage, MD

2012 Frederick R. Appelbaum, MD

2013 – Alan F. List, MD

2014 – Ian W. Flinn, MD, PhD

2015 - Judith Karp, MD

2016 – Stephan Moll, MD

2017 – S. Vincent Rajkumar, MD

2018 – David Maloney, MD

2019 – William H. Matsui, MD

2020 – Jerald Radich, MD



Baylor Charles A. Sammons Cancer Center, Dallas